Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amalia Gastaldelli

Showing results (1-10 of 317) with videos related to

Pageof 32
Sort By:
Hypertension Research : Official Journal of the Japanese Society of Hypertension|May 14, 2010
Fatty liver disease: the hepatic manifestation of metabolic syndromeAmalia Gastaldelli
Hepatobiliary Surgery and Nutrition|June 13, 2022
Is it necessary to target lipid metabolism in different organs for effective treatment of NASH?-the results of the Pan-PPAR Lanifibranor trialAmalia Gastaldelli
Diabetes Research and Clinical Practice|August 26, 2011
Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitusAmalia Gastaldelli
Obesity (Silver Spring, Md.)|July 27, 2022
Measuring and estimating insulin resistance in clinical and research settingsAmalia Gastaldelli
The Journal of Clinical Endocrinology and Metabolism|October 22, 2024
Time to Increase Awareness and Diagnosis of Steatotic Liver Disease (MASLD) in AdolescentsAmalia Gastaldelli
Cell Metabolism|March 4, 2026
Why timing matters in MASLD: Late-day metabolic controlAmalia Gastaldelli
Journal of Hepatology|September 6, 2025
From Glucose Control to Energy Expenditure and Fat Oxidation: The Emerging Role of Glucagon Agonism in Obesity and MASLDAmalia Gastaldelli
The American Journal of Clinical Nutrition|May 13, 2008
Abdominal fat: does it predict the development of type 2 diabetes?Amalia Gastaldelli
Clinical Science (London, England : 1979)|November 8, 2017
Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?Amalia Gastaldelli
Journal of Hepatology|March 15, 2025
Metabolic effects and mechanism of action of the pan-PPAR agonist lanifibranorSilvia Sabatini, Amalia Gastaldelli
Pageof 32

Showing results (1-10 of 317) with videos related to

Sort By:
Pageof 32
Hypertension Research : Official Journal of the Japanese Society of Hypertension|May 14, 2010
Fatty liver disease: the hepatic manifestation of metabolic syndromeAmalia Gastaldelli
Hepatobiliary Surgery and Nutrition|June 13, 2022
Is it necessary to target lipid metabolism in different organs for effective treatment of NASH?-the results of the Pan-PPAR Lanifibranor trialAmalia Gastaldelli
Diabetes Research and Clinical Practice|August 26, 2011
Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitusAmalia Gastaldelli
Obesity (Silver Spring, Md.)|July 27, 2022
Measuring and estimating insulin resistance in clinical and research settingsAmalia Gastaldelli
The Journal of Clinical Endocrinology and Metabolism|October 22, 2024
Time to Increase Awareness and Diagnosis of Steatotic Liver Disease (MASLD) in AdolescentsAmalia Gastaldelli
Cell Metabolism|March 4, 2026
Why timing matters in MASLD: Late-day metabolic controlAmalia Gastaldelli
Journal of Hepatology|September 6, 2025
From Glucose Control to Energy Expenditure and Fat Oxidation: The Emerging Role of Glucagon Agonism in Obesity and MASLDAmalia Gastaldelli
The American Journal of Clinical Nutrition|May 13, 2008
Abdominal fat: does it predict the development of type 2 diabetes?Amalia Gastaldelli
Clinical Science (London, England : 1979)|November 8, 2017
Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?Amalia Gastaldelli
Journal of Hepatology|March 15, 2025
Metabolic effects and mechanism of action of the pan-PPAR agonist lanifibranorSilvia Sabatini, Amalia Gastaldelli
Pageof 32